Table 1.
Demographic and clinical characteristics of chronic ITP patients before and during treatment with thrombopoietic agents
| Patient no. | Age, y | Sex | Splenectomy | Platelets, ×109/L | Thrombopoietic agent (time on treatment) at time of blood sampling/collection | Previous/ongoing non-TPO-R agonist treatment type at time of blood sampling/collection | |
|---|---|---|---|---|---|---|---|
| Pretreatment | |||||||
| 1 | 67 | Female | Yes | 29 | None | 5 mo before IVIg | |
| 2 | 66 | Female | Yes | 10 | None | 4 mo before IVIg | |
| 3 | 56 | Female | Yes | 10 | None | 17 d before IVIg | |
| 4 | 70 | Male | No | 22 | None | Daily low-dose prednisone | |
| 5 | 35 | Female | No | 23 | None | 3 w before IVIg/steroid | |
| 6 | 45 | Female | No | 22 | None | Daily low-dose prednisone | |
| 7 | 70 | Male | No | 12 | None | Daily 60-mg/mL dose prednisone | |
| 8 | 17 | Female | No | 31 | None | 3 mo before anti-D | |
| 9 | 46 | Female | No | 26 | None | 3 mo before anti-D | |
| 10 | 61 | Female | No | 36 | None | Daily low-dose prednisone | |
| On treatment | |||||||
| Same as patient 9 | 46 | Female | No | 66 | AKR-501 (for 4 mo) | — | |
| Same as patient 10 | 61 | Female | No | 290 | AKR-501 (for 4 mo) | Daily low-dose prednisone | |
| 11 | 53 | Female | Yes | 49 | Romiplostim (for 5 y) | — | |
| 12 | 52 | Male | Yes | 31 | Romiplostim (for 5 y) | — | |
| 13 | 70 | Female | No | 206 | AKR-501 (for 4 mo) | — | |
| 14 | 80 | Female | No | 140 | AKR-501 (for 4 mo) | — | |
| 15 | 51 | Female | No | 280 | Eltrombopag (for 1 y) | — | |
| 16 | 55 | Female | No | 154 | Romiplostim (for 5 y) | — | |
| 17 | 71 | Female | Yes | 70 | Romiplostim (for 5 y) | — |
All patients “on treatment” were considered responsive to the thrombopoietic agents, where responsiveness is defined as increasing the platelet count from > 30 × 109/L before starting treatment to a count usually > 50 × 109/L while on treatment. The platelet counts correspond to the patients' counts on the day their blood was analyzed for this study. Thus, although patient 12 had a platelet count of 31 × 109/L when we collected blood for our analysis, the common count for this patient while on treatment was > 50 × 109/L. Of a total of 17 patients, 3 patients were receiving daily low-dose (< 3 mg) immunosuppressive prednisone regimen and one on higher dose (60-mg) at the time of their visit, and all except one (patient 10) was in the pretreatment group.
IVIg indicates intravenous immunoglobulin; and —, none.